key: cord-1041267-41teigao authors: Russo, Alessandro; Venditti, Mario; Ceccarelli, Giancarlo; Mastroianni, Claudio Maria; d’Ettorre, Gabriella title: Procalcitonin in daily clinical practice: an evergreen tool also during a pandemic date: 2021-02-12 journal: Intern Emerg Med DOI: 10.1007/s11739-021-02659-2 sha: 8c894ea94c35ba5ff263d48e9a1b52eb55bbb038 doc_id: 1041267 cord_uid: 41teigao nan To date, PCT can be considered a useful tool for clinicians to manage at time of hospitalization patients with suspected infection by SARS-CoV-2 and to promptly distinguish this population from patients with bacterial etiology (see Fig. 1 ) [5] . Moreover, PCT results as one of the most important determinant to early detect and to monitor bacterial coinfections and superinfections in COVID-19 patients [5, 6] . Of importance, in a recent experience on 1461 patients with COVID-19, a PCT value > 0.5 ng/mL increased the risk of in-hospital mortality [7] . Finally, in a meta-analysis about risk factors for severity and death during COVID-19, a PCT value > 0.5 ng/mL was associated with a higher risk of progression to critical illness [8] . In vitro and in vivo models showed that PCT synthesis is stimulated by IL-6 and TNFα increase [9] . The inflammatory responses induced in immune cells (but also epithelial and endothelial cells) were demonstrated to be crucial in stimulating a cytokine storm, leading to severe injury also in COVID-19 patients [10] . IL-6 is considered to be one of the key mediator of this cytokine storm, causing lung injury and the progression of COVID-19. As reported in several studies, the levels of serum IL-6 were elevated and IL-6 receptors were significantly expressed in patients affected by SARS-CoV-2 infection [11, 12] . Thus, high PCT values may be associated with severity of SARS-CoV-2 infection and the measurement of PCT, especially in the first days of hospitalization, may help physicians to assess the hyper inflammatory activity and to rule out bacterial and fungal coinfection or superinfection [13, 14] . However, research is needed to clarify if the increase in serum inflammatory markers is directly caused by SARS-CoV-2 or should be considered an indirect consequence of patients' clinical status, especially in a population with chronic diseases that, like infectious diseases, can trigger a chronic proinflammatory state. Patients with such comorbidities are more likely to develop severe COVID-19 than healthy patients, at least partly for a dysfunction of innate immune response, increasing the risk of COVID-19 1 3 progression. Monitoring inflammatory markers may represent as an early warning system for progression to a more severe clinical condition. It is important to underline that monitoring PCT levels can allow early detection of bacterial infections, which may reduce inappropriate prescription of antibiotics or trigger an early antibiotic therapy to treat the first stage of sepsis and other severe infective conditions [15] . Of importance, all the observed advantages associated with PCT utilization in the study of Johnson et al. were limited to patients not requiring intensive care unit (ICU) admission [4] . In this context, the use of PCT resulted to be more efficacious in ICU patients where the decrease of PCT of > 80% over 72 h from ICU admission may provide prognostic information in critically ill patients and drive physicians to the discontinuation of antibiotic therapy [16] [17] [18] . In conclusion, the high PCT values reported in COVID-19 patients could be associated with the severity of infection and not only with the presence of bacterial coinfection or superinfection; for all these reasons, the combination of patient's clinical status with laboratory tests and imaging is crucial in daily practice to assess the likelihood of bacterial coinfection in patients with COVID-19 [19] , (see Fig. 1 ). PCT should be included in a diagnostic stewardship to apply the well-known strategies for an appropriate antimicrobial prescription [20] . Conflict of interest The authors declare that they have no conflict of interest. Informed consent Not applicable. Procalcitonin: where are we now? Role of procalcitonin in bacteremic patients and its potential use in predicting infection etiology Role of procalcitonin in predicting etiology in bacteremic patients: report from a large single-center experience Clinical outcomes and costs associated with procalcitonin utilization in hospitalized patients with pneumonia, heart failure, viral respiratory infection, or chronic obstructive pulmonary disease Comparison between hospitalized patients affected or not by COVID-19 2020) Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study Early predictors of inhospital mortality in patients with COVID-19 in a large American cohort Risk factors of critical and mortal COVID-19 cases: a systematic literature review and meta-analysis Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19 Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19) Pulmonary aspergillosis: an evolving challenge for diagnosis and treatment Association of elevated inflammatory markers and severe COVID-19: a meta-analysis Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients Procalcitonin in the assessment of ventilator associated pneumonia: a systematic review Comparison between procalcitonin and C-reactive protein to predict blood culture results in ICU patients Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials